1-苄基-6-甲基-3-哌啶醇 | 343952-88-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 1-苄基-6-甲基-3-哌啶醇
• 英文名称: 1-benzyl-6-methyl-3-piperidinol
• 英文别名: 1-Benzyl-6-methylpiperidin-3-ol
• CAS: 343952-88-5
• 化学式: C₁₃H₁₉NO
• 分子量: 205.3
• InChiKey: YUFLNFVILZVKBO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  23.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-苄基-6-甲基-3-哌啶醇 在 chromium(VI) oxide 作用下， 以74%的产率得到N-benzyl-6-methyl-3-piperidone
  参考文献：
  名称：

  Balsamo; Barili; Gagliardi, European Journal of Medicinal Chemistry, 1982, vol. 17, # 3, p. 285 - 289

  摘要：

  DOI：
• 作为产物：
  描述：

  6-甲基哌啶-3-醇 、 氯化苄 在 氢氧化钾 作用下， 以 乙醇 为溶剂， 反应 13.0h， 以52%的产率得到1-苄基-6-甲基-3-哌啶醇
  参考文献：
  名称：

  Balsamo; Barili; Gagliardi, European Journal of Medicinal Chemistry, 1982, vol. 17, # 3, p. 285 - 289

  摘要：

  DOI：

文献信息

• [EN] 2-PYRIDYLOXY-4-ETHER OREXIN RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES 2-PYRIDYLOXY-4-ÉTHER DES RÉCEPTEURS DE L'OREXINE
  申请人：MERCK SHARP & DOHME

  公开号：WO2014137883A1

  公开（公告）日：2014-09-12

  The present invention is directed to 2-pyridyloxy-4-ether compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the 2-pyridyloxy-4-ether compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved..

  本发明涉及2-吡啶氧基-4-醚化合物，这些化合物是促进睡眠的受体拮抗剂。本发明还涉及在潜在治疗或预防神经系统和精神疾病中使用本文所述的2-吡啶氧基-4-醚化合物。本发明还涉及包括这些化合物的药物组合物。本发明还涉及在预防或治疗涉及促进睡眠的受体的这些疾病中使用这些药物组合物。
• [EN] 2-PYRIDYLOXY-3-SUBSTITUTED-4-NITRILE OREXIN RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DU RÉCEPTEUR DE LA 2-PYRIDYLOXY-3-SUBSTITUÉE-4-NITRILE ORÉXINE
  申请人：MERCK SHARP & DOHME

  公开号：WO2014066196A1

  公开（公告）日：2014-05-01

  The present invention is directed to 2-pyridyloxy-3-substituted-4-nitrile compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the 2-pyridyloxy-3-substituted-4-nitrile compounds described herein in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.

  本发明涉及2-吡啶氧基-3-取代-4-腈化合物，其是促进睡眠荷尔蒙受体的拮抗剂。本发明还涉及使用本文所述的2-吡啶氧基-3-取代-4-腈化合物在治疗或预防神经系统和精神疾病中的用途，其中涉及促进睡眠荷尔蒙受体。本发明还涉及包含这些化合物的制药组合物。本发明还涉及使用这些制药组合物在预防或治疗涉及促进睡眠荷尔蒙受体的疾病中的用途。
• [EN] 2-PYRIDYLOXY-3-NITRILE-4-SUBSTITUTED OREXIN RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DES RÉCEPTEURS DE L'OREXINE À BASE DE 2-PYRYDYLOXY-3-NITRILE SUBSTITUÉ EN 4
  申请人：MERCK SHARP & DOHME

  公开号：WO2014099698A1

  公开（公告）日：2014-06-26

  The present invention is directed to 2-pyridyloxy-3-nitrile-4-substituted compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the 2-pyridyloxy-3-nitrile-4-substituted compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.

  本发明涉及2-吡啶氧基-3-腈基-4-取代化合物，其为觉醒素受体的拮抗剂。本发明还涉及使用本文所述的2-吡啶氧基-3-腈基-4-取代化合物在潜在的神经和精神障碍和疾病的治疗或预防中，这些疾病和障碍涉及觉醒素受体。本发明还涉及包含这些化合物的制药组合物。本发明还涉及使用这些制药组合物在预防或治疗涉及觉醒素受体的这些疾病中。
• [EN] HALO AND TRIFLUOROMETHYL SUBSTITUTED OREXIN RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DES RÉCEPTEURS DE L'OREXINE SUBSTITUÉS PAR DES GROUPES HALO ET TRIFLUOROMÉTHYLE
  申请人：MERCK SHARP & DOHME

  公开号：WO2014176146A1

  公开（公告）日：2014-10-30

  The present invention is directed to halo and trifluoromethyl substituted compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.

  本发明涉及卤代和三氟甲基取代化合物，其为促进醒觉素受体拮抗剂。本发明还涉及上述化合物在潜在的神经和精神障碍和疾病的治疗或预防中的应用，其中醒觉素受体参与其中。本发明还涉及包含这些化合物的制药组合物。本发明还涉及这些制药组合物在预防或治疗醒觉素受体参与的这些疾病中的应用。
• [EN] 2-PYRIDYLOXY-3-ESTER-4-NITRILE OREXIN RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DE TYPE 2-PYRIDYLOXY-3-ESTER-4-NITRILE DES RÉCEPTEURS D'OREXINES
  申请人：MERCK SHARP & DOHME

  公开号：WO2014062533A1

  公开（公告）日：2014-04-24

  The present invention is directed to 2-pyridyloxy-3-ester-4-nitrile compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the 2-pyridyloxy-3-ester-4-nitrile compounds described herein in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.

  本发明涉及对俄利新受体拮抗剂的2-吡啶氧基-3-酯基-4-腈类化合物。本发明还涉及所述2-吡啶氧基-3-酯基-4-腈类化合物在治疗或预防神经和精神疾病中的用途，这些疾病中涉及俄利新受体。本发明还涉及含有这些化合物的药物组合物。本发明还涉及这些药物组合物在预防或治疗涉及俄利新受体的疾病中的用途。